Scientists at NYU Langone Health have discovered a new drug aimed at reducing the severe effects of diabetes, offering a potential ray of hope for millions of patients worldwide.
According to the report, the drug has been named RAGE406R. In experimental studies conducted on mice, it proved effective in reducing inflammation, limiting cellular damage, and improving recovery of the heart and kidneys. The drug also accelerated the wound-healing process in diabetic subjects, which is considered a major challenge for diabetes patients.
Experts say this drug works differently from existing diabetes medications. Instead of lowering blood sugar levels, it prevents damage occurring inside the cells.
The drug works by blocking the interaction between two harmful proteins, RAGE and DIAPH1, thereby reducing the damaging effects of Advanced Glycation End Products (AGEs).
Advanced Glycation End Products are substances formed when sugar binds with proteins or fats, and their levels increase in diabetes. When these substances bind to the RAGE protein, inflammation and cellular damage increase.
According to the research, applying the drug to the skin of mice resulted in faster wound healing, indicating that it may help treat slow healing wounds in diabetes patients.
The study has been published in the journal Cell Chemical Biology and, despite being in its early stages, is being viewed as a significant advancement in diabetes treatment.
If successful in human trials, the drug could offer new hope for patients with both type 1 and type 2 diabetes.
